Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVAT 021

Next Previous
Drug Profile

AVAT 021

Alternative Names: AVAT-021; Cannabidiol oral - Avata Biosciences; SAP-021; SAP-021-T1; SAP-021-T2; Solid dose CBD - Avata Biosciences

Latest Information Update: 26 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sapient Therapeutics
  • Developer Avata Biosciences
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
  • Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Neurological disorders
  • Clinical Phase Unknown Psychiatric disorders

Most Recent Events

  • 18 Jun 2025 Avata Biosciences and Oceanus Bio agree to co-develop AVAT 022 in Japan and Asia, excluding China and India
  • 13 May 2024 Avata Biosciences plans to achieve FDA approval and a US commercial launch of SAP-021 in 2028.
  • 13 May 2024 Avata Biosciences plans a clinical study for SAP-021 in the second half of 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top